Testosterone Treatment (TTh) Improves Anemia and Hematocrit Increase Reduced Death in Hypogonadal Men: Paradigm Shift of a Risk Factor of TTh

Abstract

Testosterone Treatment (TTh) Improves Anemia and Hematocrit Increase Reduced Death in Hypogonadal Men: Paradigm Shift of a Risk Factor of TTh. Curr Trends Intern Abstract Real-life 12 years data show that long-term treatment with testosterone treatment has significant reduction in mortality [1-3] and increase of hematocrit, which theoretically could increase risk of fatal cardiovascular events, could not be proven [4]. Summarizing results of research results that aimed to throw the light on the relationship between hematocrit and all-cause mortality in men receiving TTh in long-term setting [5,6].